Invokana (canagliflozin) is an inhibitor of sodium-glucose co-transporter 2 (SGLT2) which is a FDA-approved medication and is used for treating type 2 diabetes mellitus in adults. It is strictly prohibited for using it in the treatment of type 1 diabetes mellitus.
Invokana was launched as a Janssen’s product and given its easy dietary restrictions, it quickly made its way as one of the most popular medications for diabetes. Unfortunately, soon after it was released, there were plenty of negative reports. In fact, in May 2015, the FDA warned about Invokana’s potentially life-threatening side-effect diabetic ketoacidosis (with excess amount of ketones in the body) became a serious concern in the medical industry. In September 2015, there was a revised FDA warning highlighting how invokana can increase the risk of bone fracture and decreased bone mineral density.
The invokana lawsuit update allows the victims of this drug to claim for the damage awards if they have suffered from any of the above stated complications.
The following side effects have been most frequently reported by patients who are taking invokana:
- amputation of lower limb
- impairment of renal function
- acute kidney complications
- increased low-density lipoprotein
- bone fracture
According to invokana lawsuit update, the injured patients alleged Janssen Pharmaceuticals of the following points:
- not disclosing the clear information to the FDA
- failed to mention the risks of taking invokana
- did not conduct proper clinical safety trials
- failed to warn both the patients and doctors of the life-threatening side effects
Current status of invokana lawsuits
There are no known group settlements presently involving the use of Invokana. During the last months of 2015, a couple of lawsuits were filed in Missouri and Illinois. The lawsuits need to sort out the specific interaction linked within the renal failure and use of Invokana.
Your voice matters
The invokana lawyers help to fight against the pharmaceutical giants.